Medexus Pharmaceuticals (TSX:MDP) ROCE % : 7.40% (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medexus Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 7.40%.

Medexus Pharmaceuticals ROCE % Historical Data

The historical data trend for Medexus Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals ROCE % Chart

Medexus Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

1.65

-20.95

8.45

10.56

16.02

Medexus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															17.71	8.93	14.08	17.82	7.40

Medexus Pharmaceuticals ROCE % Calculation

Medexus Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	18.233	/	( ( (220.746 - 114.248)	+	(210.8 - 89.648) )	/ 2 )
	=	18.233	/	( (106.498	+	121.152)	/ 2 )
	=	18.233	/	113.825
	=	16.02 %

Medexus Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	8.572	/	( ( (201.823 - 81.183)	+	(196.914 - 85.945) )	/ 2 )
	=	8.572	/	( ( 120.64	+	110.969 )	/ 2 )
	=	8.572	/	115.8045
	=	7.40 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Medexus Pharmaceuticals (TSX:MDP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medexus Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MEDXF:USA

Address

10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3

Website

https://www.medexus.com

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

Executives

Brendon Buschman	Senior Officer
Benoit Gravel	Director
Stephen William Nelson	Director
Kenneth D'entremont	Director, Senior Officer
Mike Mueller	Director
Marcel Pascal Konrad	Senior Officer
Brian Peters	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin	Senior Officer
Michael Pine	Senior Officer
Glenn Tate	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle	Senior Officer
Benoît Hébert	Senior Officer